Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine
- PMID: 2752392
- PMCID: PMC11038281
- DOI: 10.1007/BF00199212
Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine
Abstract
Urinary-tumor-associated antigen (U-TAA) is a glycoprotein present in the urine of melanoma patients. Previous studies have addressed the role of U-TAA in immunoprognosis. The present investigation was undertaken to determine whether the administration of whole melanoma cell vaccine (MCV) could induce the formation of anti-(U-TAA) antibodies in melanoma patients. The subjects of this study were stage II and III melanoma patients receiving MCV alone or in conjunction with cyclophosphamide. Anti-(U-TAA) IgM and IgG antibody levels were determined by enzyme immunoassay in sequential serum samples from 15 stage II and III melanoma patients receiving MCV. U-TAA purified from the urine of a melanoma patient was used as a target in this assay. The mean anti-(U-TAA) IgM titer prior to vaccination was similar to that of a non-vaccinated melanoma control group (1:1138 +/- 214, n = 15 vs 1:1334 +/- 254, n = 7; P = 0.375) but prevaccination IgG levels were generally higher than in the control group (1:3984 +/- 602 vs 1:2595 +/- 423; 0.1 greater than P greater than 0.05). While only 6 of the 15 patients demonstrated a rise in levels of IgG antibodies (mean 1:2964 +/- 1047 pre-MCV to 1:9958 +/- 2677 post MCV, P less than 0.01), 11 of the 15 patients demonstrated a greater than twofold rise in their anti-(U-TAA) IgM titers following vaccination (1:1051 +/- 259 pre-MCV to 1:2518 +/- 576 post-MCV; P less than 0.005). In addition, patients with visceral metastases consistently elicited anti-(U-TAA) responses equivalent to those with more limited disease. Concomitant administration of cyclophosphamide did not affect the response rates of peak antibody levels. The possibility that these antibody responses were actually against histocompatibility locus antigens (HLA) (contaminating our U-TAA preparation) was ruled out because the target antigen (U-TAA) was devoid of HLA, and because the induction of anti-(U-TAA) antibodies did not correlate with the induction of anti-HLA antibodies. These results demonstrate augmentation of anti-(U-TAA) IgM and IgG antibodies by immunization with the MCV.
Similar articles
-
Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.Ann Surg Oncol. 1996 Sep;3(5):437-45. doi: 10.1007/BF02305761. Ann Surg Oncol. 1996. PMID: 8876885
-
Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.J Immunol. 1995 Jan 15;154(2):730-7. J Immunol. 1995. PMID: 7814879
-
Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.Cancer Immunol Immunother. 1997 Jan;43(6):324-30. doi: 10.1007/s002620050340. Cancer Immunol Immunother. 1997. PMID: 9067403 Free PMC article.
-
Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2805-9. doi: 10.1073/pnas.92.7.2805. Proc Natl Acad Sci U S A. 1995. PMID: 7708728 Free PMC article.
-
Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine.J Clin Immunol. 1998 Jul;18(4):299-305. doi: 10.1023/a:1027342024618. J Clin Immunol. 1998. PMID: 9710747
Cited by
-
Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor-associated antigen.Cancer Immunol Immunother. 1990;32(4):214-20. doi: 10.1007/BF01741703. Cancer Immunol Immunother. 1990. PMID: 1702032 Free PMC article.
-
Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.Ann Surg Oncol. 1996 Sep;3(5):437-45. doi: 10.1007/BF02305761. Ann Surg Oncol. 1996. PMID: 8876885
-
Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor.ACS Nano. 2019 Jun 25;13(6):6477-6490. doi: 10.1021/acsnano.8b09613. Epub 2019 May 17. ACS Nano. 2019. PMID: 31100004 Free PMC article.
-
Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function.Neoplasia. 2003 Jan-Feb;5(1):3-8. doi: 10.1016/s1476-5586(03)80011-8. Neoplasia. 2003. PMID: 12659664 Free PMC article. Review.
-
Nanosystems for Improved Targeted Therapies in Melanoma.J Clin Med. 2020 Jan 23;9(2):318. doi: 10.3390/jcm9020318. J Clin Med. 2020. PMID: 31979325 Free PMC article. Review.
References
-
- Berd D, Maquire HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986;46:2572. - PubMed
-
- Burk MW, Saxton RE, Meier SJ, Morton DL. Immune cytolysis of human malignant melanoma by antibody to oncofetal antigen-I (OFA-I). II. Antibody-dependent cell mediated cytotoxicity. Surg Forum. 1980;31:427.
-
- Carrel S, Accolla RS, Carmagnola AL, Mach JP. Common human melanoma-associated antigen(s) detected by monoclonal antibodies. Cancer Res. 1980;40:2523. - PubMed
-
- Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of stage II malignant melanoma with New Castle Disease Viral Oncolysate. Cancer. 1973;52:856. - PubMed
-
- Chee DO, Gupta RK, Morton DL. Humeral response of melanoma patients to two different tumor-associated antigens. J Surg Oncol. 1983;23:228. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials